VIKING THERAPEUTICS INC (VKTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$32.70-2.91%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Viking Therapeutics is advancing its pipeline with a new chief medical officer. The company focuses on metabolic and endocrine disorders, which have strong demand. Despite losses, recent progress in obesity drug VK2735 could lead to future value. The stock price is down over 55%, reflecting current challenges but also potential upside if development succeeds.
The company continues to report losses with EPS around -$1.37 next quarter and worsening yearly EPS estimates near -$4.7. Multiple recent earnings misses show execution risks. There is no current revenue, and the market expects negative growth. Pipeline setbacks or regulatory issues could delay or derail progress.
The market price is about 56% below the consensus valuation level near $95. This reflects expectations of ongoing losses and uncertain pipeline success. Our view aligns with the Street median valuation but sees risk in the company’s ability to reach profitability.
Breaks if: cash runway falls below 12 months without clear financing plan
Breaks if: EPS loss worsens beyond -$1.5 next quarter or fails to improve by end 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. VKTX is in the healthcare sector, specifically targeting obesity treatments, and is currently in a watch state due to mixed recent performance.
The market appears to price in a low level of fragility, suggesting that investors are not overly concerned about immediate risks. However, the company's recent financial performance has been weaker than its peers, indicating that expectations may be cautious.
Management is executing on key priorities, such as advancing clinical trials for VK2735 and VK3019, which are on track. However, the company remains loss-making, and recent financial performance has been weak, which could impact future results.
The long-term thesis hinges on the outcomes of ongoing clinical trials and the ability to maintain fiscal discipline amid increased R&D spending. Additionally, broader sector performance and economic conditions, such as job reports, will be crucial in shaping investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: failure to meet key clinical or regulatory milestones for VK2735 by end 2026
VKTX is in a delicate position with its focus on obesity treatments and elevated risks. The next few quarters will be critical in determining its trajectory. Not investment advice.